https://orcid.org/0009-0004-6347-493X
Figures
Abstract
Background
The incidence of childhood malnutrition i.e., both obesity and undernutrition, is on a rise. While there is extensive evidence of the influence of body mass index (BMI) on the survival and other important outcomes of adult cancers, the impact of childhood BMI on one of the common pediatric cancers i.e., leukemia is not well studied.
Methods
Systematic search of PubMed, Scopus, and Google Scholar databases was done to identify studies that were conducted among pediatric patients with leukemia and had examined outcomes of interest based on BMI at the time of diagnosis.
Results
Effect sizes were reported as pooled hazards ratio (HR) along with 95% confidence intervals (CI). A total of 17 studies were included. Compared to pediatric leukemia patients with normal BMI, underweight (HR 1.07, 95% CI: 1.04, 1.11) and obese (HR 1.42, 95% CI: 1.18, 1.71) children with leukemia had higher risks of overall mortality. Underweight (HR 1.10, 95% CI: 1.02, 1.19) and obese (HR 1.34, 95% CI: 1.15, 1.55) pediatric leukemia patients had a tendency to lower event-free survival compared to children with normal BMI. The risk of relapse was not significant for underweight, overweight, and obese children.
Citation: Dong L, Dai G, Zhao J (2024) Impact of body mass index at diagnosis on outcomes of pediatric acute leukemia: A systematic review and meta-analysis. PLoS ONE 19(5): e0302879. https://doi.org/10.1371/journal.pone.0302879
Editor: Guoying Wang, Johns Hopkins University Bloomberg School of Public Health, UNITED STATES
Received: January 16, 2024; Accepted: April 14, 2024; Published: May 6, 2024
Copyright: © 2024 Dong et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the manuscript and its Supporting information files.
Funding: The author(s) received no specific funding for this work.
Competing interests: The authors have declared that no competing interests exist.
Introduction
The incidence of childhood obesity is on the rise in the developed countries [1]. Concurrently, in many of the countries, there is a dual burden of childhood undernutrition as well as obesity [2–4]. According to a recent global estimate, around 40 million children under five years of age are either overweight or obese [5]. On the other hand, around 45–50 million children, particularly from low- and middle-income countries suffer from wasting due to severe undernutrition [6, 7].
Leukemia is one of the most prevalent childhood cancers, and one of the leading causes of cancer-related deaths among children [8–10]. Acute lymphoblastic leukaemia (ALL) accounts for around three-fourth of all pediatric leukemia cases and is currently associated with significantly improved prognosis (5-year survival of around 80–85%) [11, 12].
Malnutrition i.e., both under and over-nutrition, has been shown to influence the outcomes in adult cancers. Obesity, for instance, has been shown to influence the survival and relapse of some adult cancers [13–15]. A credible body of evidence suggests a link between cancer prognosis and inflammation due to obesity. Adiposity that results from obesity creates a pro-inflammatory environment that could possibly contribute to adverse prognostic outcomes [16]. Obesity is associated with an increased circulating levels of inflammatory cytokines such as interleukin-6 (IL-6) and tumour necrosis factor- alpha (TNF- α) that may trigger an increase in the number of cells that have tumour-forming potential [16, 17]. On the other hand, studies demonstrate that undernutrition is associated with increased tumour aggressiveness, thereby, increasing the risk of recurrence and metastasis [17, 18]. Also, some evidence from certain adult cancers suggests that undernutrition may be associated with sub-optimal response to chemotherapy and associated side effects [19, 20].
While there is evidence of the impact of body mass index (BMI) on the outcomes of certain cancers such as bladder cancer, colon cancer, nasopharyngeal cancer etc, the impact of childhood BMI on leukemia is unclear. Two prior systematic reviews on this issue have been published [21, 22]. One review by Amankwah et al. pooled 11 studies and documented that pediatric patients with high BMI were at increased risk of mortality [21]. Similar review by Orgel et al was published in the year 2016 and demonstrated that high BMI correlated with increased risk of poor event free survival (EFS) and overall survival in children with both ALL and acute myelogenous leukemia (AML) [22]. However, both these reviews were conducted nearly half a decade ago and with the new studies on this issue being published, there is a need to update the evidence.
This study aims to assess the impact of malnutrition status on the outcomes of pediatric patients with leukemia.
Materials and methods
Search strategy, selection criteria and relevant methods
The PRISMA guidelines were followed for conducting this meta-analysis [23]. The study was registered at PROSPERO, with the number: CRD42024497221. A systematic search was conducted using structured strategy (S1 Table) across PubMed, Scopus and Google Scholar databases. This search aimed to identify English-language studies published until 15th December 2023 that examined the association between body mass index (BMI) at the time of diagnosis with overall survival, event free survival (EFS), and relapse rate in pediatric patients with leukemia.
After executing the search strategy, and deduplication, two study authors independently reviewed titles and abstracts to identify potentially relevant studies. Full texts of the studies were then read to finally select the studies for the meta-analysis. If any disagreements arose, the two authors of the study reached a shared consensus through discussion.
Eligible studies should have examined pediatric patients with confirmed leukemia diagnosis and assessed relevant outcomes based on BMI at the time of diagnosis. Standardized BMI cut-offs for pediatric populations are not universally agreed upon, and variations exist in defining categories such as underweight, normal weight, overweight, and obesity. We made a decision to combine studies with different BMI cut-offs to maximize the available data, enhance statistical power, and acknowledge the variability in BMI categorization methods across the literature. We aimed to include observational studies (either with cohort, cross-sectional or case-control design). All included studies should have reported data of the control group of pediatric leukemia patients with normal BMI.
Case reports or reviews were excluded. Also, studies that did not compare outcomes of interest based on BMI at the time of diagnosis or the outcomes reported were not relevant for this meta-analysis were excluded.
A pilot-tested data extraction sheet was employed for the extraction process. Two study authors independently gathered required data from the included studies. All disagreements were resolved by consensus. The assessment of the included studies was conducted using the Newcastle-Ottawa Quality Assessment Scale for non-randomised studies [24].
Statistical analysis
All the analyses were done using STATA version 16.0. The effect sizes were reported as pooled hazards ratio (HR) along with 95% confidence intervals (CI). Pooled effect sizes were presented for underweight, overweight, and obese categories, compared to normal BMI at the time of diagnosis. A subgroup analysis was conducted based on diagnosis of acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). We used I2 to report and assess the magnitude of heterogeneity. Random effects model was used in instances where I2 was more than 40% [25]. A P-value of less than 0.05 was considered statistically significant. Publication bias was also assessed using the Egger’s test.
Results
Database searching revealed 773 unique citations (Fig 1).
Of them, 669 studies were removed after the title screening, and additional 69 studies were removed after the abstract screening. The remaining 35 papers underwent detailed full-text review. Finally, 17 were included in the analysis [26–42].
Of these, 11 were prospective cohort studies and 6 were retrospective data analyses. Seven studies were conducted in the USA. One study each was conducted in Mexico, Canada, United Kingdom, Brazil, China and Thailand. Finally, four multi-centre studies were included. Ten studies investigated pediatric acute lymphoblastic leukemia (ALL) patients, five investigated pediatric myeloid leukemia (AML) patients, and two investigated a mixed cohort, including patients with ALL, AML, chronic myeloid leukemia, or myelodysplastic syndrome) (Table 1). The quality of the included studies was judged to be good (Table 1).
BMI was the primary exposure. Included studies differed in the BMI cut-offs adopted for defining underweight, normal and obese children. Specific criteria used by the individual studies have been presented in Table 1. The different criteria were comprised of guidelines by the International Obesity Task Force (n = 1 study), z- score based approach (n = 1 study), BMI percentile-based approach (n = 12 studies) and use of WHO/CDC criteria (n = 3 studies). The variability in the cut-offs for categorizing underweight, normal, overweight and obese children was detected even in studies that used the percentile-based approach.
Body mass index (BMI) at diagnosis and overall mortality
Underweight (HR 1.07, 95% CI: 1.04, 1.11; I2 = 0.0%, N = 12) or obese (HR 1.42, 95% CI: 1.18, 1.71; I2 = 76.6%, N = 15) pediatric leukemia patients showed greater mortality risk compared to children with normal BMI. However, no difference in mortality risk was noted in overweight children (HR 0.99, 95% CI: 0.91, 1.08; I2 = 0.0%, N = 7) (Fig 2).
We noted that for the comparison between underweight and normal BMI children, around 95% of the weight was given to the study by Eissa et al (2017) [29]. Therefore, we repeated the analysis after excluding this study. Our findings still indicated an increased risk of mortality (HR 1.17, 95% CI: 1.01, 1.35; I2 = 0.0%, N = 11) (S1 Fig). Similarly, we found that for the comparison between overweight and normal BMI children, around 60% of the weight was given to the study by Eissa et al. A sensitivity analysis that excluded this study did not detect difference in the mortality risk in overweight children (HR 1.06, 95% CI: 0.92, 1.23; I2 = 0.0%, N = 6) (S1 Fig).
Egger’s test did not detect the presence of publication bias (P = 0.40 for underweight category; P = 0.27 for overweight category; P = 0.64 for obese category). Subgroup analysis showed that underweight [ALL: HR 1.07, 95% CI: 1.02, 1.11; AML: HR 1.28, 95% CI: 1.03, 1.55] and obese [ALL: HR 1.67, 95% CI: 1.11, 2.55; AML: HR 1.41, 95% CI: 1.07, 1.83] children with ALL and AML both showed elevated risk of mortality compared to children with normal BMI (S2 Table).
Body mass index (BMI) at diagnosis and event-free mortality
Underweight (HR 1.10, 95% CI: 1.02, 1.19; I2 = 1.5%, N = 11) and obese (HR 1.34, 95% CI: 1.15, 1.55; I2 = 74.9%, N = 15) children showed lower rates of event-free survival compared to normal BMI children (Fig 3).
No significant difference in EFS was noted between overweight and normal BMI children (HR 1.07, 95% CI: 0.96, 1.19; I2 = 13.2%, N = 7). No evidence for publication bias was noted (P = 0.63 for underweight category; P = 0.59 for overweight category; P = 0.36 for obese category).
For analysis related to underweight children, around 60% of the weight was allocated to study by Eissa et al (2017) [29]. We did a re-analysis after excluding this study and noted that the association with EFS was not statistically significant (HR 1.07, 95% CI: 0.94, 1.21; I2 = 7.9%, N = 10) (S2 Fig). Similarly, we found that for the comparison between overweight and normal BMI children, around 45% of the weight was given to the study by Eissa et al. On doing a sensitivity analysis after excluding this study, no statistical difference was found in the risk of event free mortality in overweight children (HR 1.12, 95% CI: 0.95, 1.32; I2 = 20.9%, N = 6) (S2 Fig). Subgroup analysis showed that underweight [ALL: HR 1.13, 95% CI: 1.05, 1.24; AML: HR 1.16, 95% CI: 1.03, 1.37] and obese [ALL: HR 1.62, 95% CI: 1.20, 2.23; AML: HR 1.35, 95% CI: 1.14, 1.56] children with ALL and AML both showed lower EFS rates compared to children with normal BMI (S2 Table).
Body mass index (BMI) at diagnosis and risk of relapse
Risk of relapse was comparable in underweight (HR 1.06, 95% CI: 0.92, 1.22; I2 = 0.0%, N = 9), overweight (HR 0.93, 95% CI: 0.79, 1.08; I2 = 0.0%, N = 6), obese (HR 1.02, 95% CI: 0.83, 1.26; I2 = 59.6%, N = 10), and normal-BMI pediatric leukemia patients (Fig 4).
We did not find evidence of publication bias (P = 0.20 for underweight category; P = 0.31 for overweight category; P = 0.77 for obese category). Subgroup analysis showed that underweight, overweight, and obese children with ALL or AML were not at an increased risk of relapse, compared to children with normal BMI (S2 Table).
Discussion
Our review found that underweight or obese pediatric leukemia patients had higher risk of mortality and poor EFS compared to children with normal BMI. There was no increased risk of mortality or poor EFS among patients who were overweight. Subgroup analysis showed that this effect of underweight and obese status on the risk of mortality and EFS was detected in both ALL and AML patients. Our results emonstrated that the risk of relapse was statistically similar across all BMI categories (underweight, overweight and obese), when compared to normal BMI. Our findings are similar to the earlier two reviews that also noted that higher BMI is associated with increased risk of mortality and lower EFS [21, 22]. However, earlier reviews did not clarify the operational definition of “higher BMI” and had variability in comparison groups among different included studies. For some, the comparator was normal BMI, while for others it was a combination of normal and underweight BMI. Further, previous reviews did not consider other BMI categories as a “exposure of interest”. In contrast, current meta-analysis showed that both high BMI (i.e., obesity) and underweight status were risk factors for poor outcomes.
The observed association of obesity with poor outcomes may be explained by several mechanisms. Obesity may impact pharmacokinetics and/or pharmacodynamics of the chemotherapeutic drugs, particularly those that are lipophilic [43, 44]. This may, in turn, affect the efficacy of these drugs and consequently, the outcomes. Obese children with ALL are likely to be at higher risk for treatment-related toxicities, such as steroid-induced hyperglycemia, asparaginase-induced pancreatitis, hepatic steatosis and osteonecrosis [45, 46]. This can easily limit the effective administration of chemotherapy and can force dose reductions. All these factors might contribute towards decreasing the probability of survival and/or EFS in children with high BMI. Also, obesity leads to a stage of chronic inflammation that may provide conducive milieu for tumour growth [47, 48]. Childhood obesity has been shown to be associated with quite a few comorbid conditions which may further reduce the quality of life [49].
Prior studies have indicated that underweight patients are at increased risk of cancer recurrence and that underweight status increases the risk of mortality in cancer patients due to infection and associated sepsis [17, 50, 51]. We did not test the possibility of increased risk of infection and sepsis in underweight children but do believe that future studies should explore the BMI-infection-mortality pathway in pediatric cancer patients. Studies have also shown that there may be an increased risk of recurrence and metastasis in patients who are undernourished due to the increased tumour aggressiveness [17, 18]. Underweight children may experience compromised immune function and reduced physiological reserves, making them more susceptible to the adverse effects of aggressive cancer treatments. There have been suggestions that sub-optimal nutritional status might lead to an increased toxicity and possibly, a decreased response to chemotherapy [19, 20].
Both underweight and obese children may experience delays in diagnosis and initiation of treatment. Underweight children might be more vulnerable to delayed diagnosis due to atypical or less noticeable symptoms, while obesity may contribute to diagnostic challenges, masking symptoms or complicating the interpretation of laboratory results. Psychosocial factors might also play a role. Underweight children may face socioeconomic disparities and limited access to healthcare, impacting timely diagnosis and intervention. On the other hand, obese children might encounter stigma or bias in healthcare settings, potentially influencing the quality of care they receive.
We do acknowledge that there are certain limitations of this review. A noteworthy limitation is that most studies were retrospective and therefore, it is possible that some of the important variables or confounders were not adjusted in the analysis. This may make the reported effect sizes in individual studies biased. Majority of the studies failed to comprehensively report on the treatment protocols adopted for leukemia and therefore, it was not possible to elucidate how the treatment modified the observed association between BMI and the outcomes. In the included studies, the BMI was categorized into underweight, normal, overweight and obesity using different guidelines. This could have led to heterogeneity in the findings. Although we included studies from a wide geographical location, we were unable to explore the granularity of different protocols used globally. This was mainly due to the wide variation in the protocols used. The value of our analysis would have improved if we could have related the findings with the protocols (and doses of various drugs) employed in the included studies across the various country settings.
Conclusion
Based on the findings of this meta-analysis, we conclude that underweight or obese children with ALL and AML leukemia tend to have an increased risk of poor survival outcomes. Future studies should explore the underlying mechanisms that lead to poor outcomes to identify potential areas of intervention. Studies should also explore the effect of interventions to address undernutrition and obesity in pediatric leukemia patients on the disease outcome.
Supporting information
S1 Table. Search strategy for identification of studies to be included in the review.
https://doi.org/10.1371/journal.pone.0302879.s001
(DOCX)
S2 Table. Findings of the subgroup analysis based on the type of pediatric leukaemia.
https://doi.org/10.1371/journal.pone.0302879.s002
(DOCX)
S1 Fig. Sensitivity analysis for overall survival, after excluding the study by Eissa et al (2017).
https://doi.org/10.1371/journal.pone.0302879.s003
(TIF)
S2 Fig. Sensitivity analysis for event free survival, after excluding the study by Eissa et al (2017).
https://doi.org/10.1371/journal.pone.0302879.s004
(TIF)
References
- 1. Di Cesare M, Sorić M, Bovet P, Miranda JJ, Bhutta Z, Stevens GA, et al. The epidemiological burden of obesity in childhood: a worldwide epidemic requiring urgent action. BMC Medicine. 2019;17: 212. pmid:31760948
- 2. Sahoo K, Sahoo B, Choudhury AK, Sofi NY, Kumar R, Bhadoria AS. Childhood obesity: causes and consequences. J Family Med Prim Care. 2015;4: 187–192. pmid:25949965
- 3. Seidell JC, Halberstadt J. The global burden of obesity and the challenges of prevention. Ann Nutr Metab. 2015;66 Suppl 2: 7–12. pmid:26045323
- 4. Gupta N, Goel K, Shah P, Misra A. Childhood obesity in developing countries: epidemiology, determinants, and prevention. Endocr Rev. 2012;33: 48–70. pmid:22240243
- 5.
2018 Global Nutrition Report. [cited 21 Sep 2021]. https://globalnutritionreport.org/reports/global-nutrition-report-2018/
- 6. Ssentongo P, Ssentongo AE, Ba DM, Ericson JE, Na M, Gao X, et al. Global, regional and national epidemiology and prevalence of child stunting, wasting and underweight in low- and middle-income countries, 2006–2018. Sci Rep. 2021;11: 5204. pmid:33664313
- 7. Kinyoki DK, Osgood-Zimmerman AE, Pickering BV, Schaeffer LE, Marczak LB, Lazzar-Atwood A, et al. Mapping child growth failure across low- and middle-income countries. Nature. 2020;577: 231–234. pmid:31915393
- 8. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA: A Cancer Journal for Clinicians. 2014;64: 83–103. pmid:24488779
- 9. Metayer C, Dahl G, Wiemels J, Miller M. Childhood Leukemia: A Preventable Disease. Pediatrics. 2016;138: S45–S55. pmid:27940977
- 10. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7: e577. pmid:28665419
- 11. Pui C-H, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371: 1030–1043. pmid:18358930
- 12. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381: 1943–1955. pmid:23523389
- 13. Sinicrope FA, Foster NR, Yothers G, Benson A, Seitz JF, Labianca R, et al. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer. 2013;119: 1528–1536. pmid:23310947
- 14. Ko SH, Han KD, Yun JS, Chung S, Koh ES. Impact of obesity and diabetes on the incidence of kidney and bladder cancers: a nationwide cohort study. Eur J Endocrinol. 2019;181: 489–498. pmid:31509802
- 15. Petrelli F, Cortellini A, Indini A, Tomasello G, Ghidini M, Nigro O, et al. Association of Obesity With Survival Outcomes in Patients With Cancer: A Systematic Review and Meta-analysis. JAMA Network Open. 2021;4: e213520. pmid:33779745
- 16. Kolb R, Sutterwala FS, Zhang W. Obesity and cancer: inflammation bridges the two. Curr Opin Pharmacol. 2016;29: 77–89. pmid:27429211
- 17. Moon H-G, Han W, Noh D-Y. Underweight and breast cancer recurrence and death: a report from the Korean Breast Cancer Society. J Clin Oncol. 2009;27: 5899–5905. pmid:19805676
- 18. Huang P-Y, Wang C-T, Cao K-J, Guo X, Guo L, Mo H-Y, et al. Pretreatment body mass index as an independent prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: findings from a randomised trial. Eur J Cancer. 2013;49: 1923–1931. pmid:23434149
- 19. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Benson AB, Macdonald JS, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003;98: 484–495. pmid:12879464
- 20. Kizer NT, Thaker PH, Gao F, Zighelboim I, Powell MA, Rader JS, et al. The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer. 2011;117: 948–956. pmid:20945318
- 21. Amankwah EK, Saenz AM, Hale GA, Brown PA. Association between body mass index at diagnosis and pediatric leukemia mortality and relapse: a systematic review and meta-analysis. Leukemia & Lymphoma. 2016;57: 1140–1148. pmid:26453440
- 22. Orgel E, Genkinger JM, Aggarwal D, Sung L, Nieder M, Ladas EJ. Association of body mass index and survival in pediatric leukemia: a meta-analysis. Am J Clin Nutr. 2016;103: 808–817. pmid:26864366
- 23.
PRISMA. [cited 11 Sep 2021]. http://www.prisma-statement.org/PRISMAStatement/
- 24. Wells G, Shea B, O’Connell D, Robertson J, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta- Analysis.: 21.
- 25.
Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions : Cochrane Book Series.: 674.
- 26. Egnell C, Ranta S, Banerjee J, Merker A, Niinimäki R, Lund B, et al. Impact of body mass index on relapse in children with acute lymphoblastic leukemia treated according to Nordic treatment protocols. European Journal of Haematology. 2020;105: 797–807. pmid:32909636
- 27. Martín-Trejo JA, Núñez-Enríquez JC, Fajardo-Gutiérrez A, Medina-Sansón A, Flores-Lujano J, Jiménez-Hernández E, et al. Early mortality in children with acute lymphoblastic leukemia in a developing country: the role of malnutrition at diagnosis. A multicenter cohort MIGICCL study. Leuk Lymphoma. 2017;58: 898–908. pmid:27561220
- 28. Løhmann DJA, Asdahl PH, Abrahamsson J, Ha S-Y, Jónsson ÓG, Kaspers GJL, et al. Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia. Cancer Med. 2019;8: 6634–6643. pmid:31532076
- 29. Eissa HM, Zhou Y, Panetta JC, Browne EK, Jeha S, Cheng C, et al. The effect of body mass index at diagnosis on clinical outcome in children with newly diagnosed acute lymphoblastic leukemia. Blood Cancer J. 2017;7: e531. pmid:28212374
- 30. Aldhafiri FK, McColl JH, Reilly JJ. Prognostic significance of being overweight and obese at diagnosis in children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2014;36: 234–236. pmid:24276040
- 31. Hijiya N, Panetta JC, Zhou Y, Kyzer EP, Howard SC, Jeha S, et al. Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood. 2006;108: 3997–4002. pmid:16917005
- 32. Orgel E, Sposto R, Malvar J, Seibel NL, Ladas E, Gaynon PS, et al. Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children’s Oncology Group. J Clin Oncol. 2014;32: 1331–1337. pmid:24687836
- 33. Orgel E, Tucci J, Alhushki W, Malvar J, Sposto R, Fu CH, et al. Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia. Blood. 2014;124: 3932–3938. pmid:25349177
- 34. Canner J, Alonzo TA, Franklin J, Freyer DR, Gamis A, Gerbing RB, et al. Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children’s Oncology Group. Cancer. 2013;119: 4162–4169. pmid:24104395
- 35. Inaba H, Surprise HC, Pounds S, Cao X, Howard SC, Ringwald-Smith K, et al. Effect of body mass index on the outcome of children with acute myeloid leukemia. Cancer. 2012;118: 5989–5996. pmid:22648558
- 36. Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S, et al. Outcomes in CCG-2961, a children’s oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children’s oncology group. Blood. 2008;111: 1044–1053. pmid:18000167
- 37. Aplenc R, Zhang M-J, Sung L, Zhu X, Ho VT, Cooke K, et al. Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation. Blood. 2014;123: 3504–3511. pmid:24711663
- 38. Bulley S, Gassas A, Dupuis LL, Aplenc R, Beyene J, Greenberg ML, et al. Inferior outcomes for overweight children undergoing allogeneic stem cell transplantation. Br J Haematol. 2008;140: 214–217. pmid:18028482
- 39. Gelelete CB, Pereira SH, Azevedo AMB, Thiago LS, Mundim M, Land MGP, et al. Overweight as a prognostic factor in children with acute lymphoblastic leukemia. Obesity (Silver Spring). 2011;19: 1908–1911. pmid:21720424
- 40. Surapolchai P, Pakakasama S, Sirachainan N, Anurathapan U, Songdej D, Chuansumrit A, et al. Comparative outcomes of Thai children with acute lymphoblastic leukemia treated with two consecutive protocols: 11-year experience. Leuk Lymphoma. 2012;53: 891–900. pmid:21988642
- 41. Hu W, Cheung YT, Tang Y, Hong L, Zhu Y, Chen J, et al. Association between body mass index at diagnosis and outcomes in Chinese children with newly diagnosed acute lymphoblastic leukemia. Cancer Med. 2023;12: 2850–2860. pmid:36168702
- 42. Iijima M, Stall M, Wang L, Panetta JC, Triplett BM, Pui C-H, et al. Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome. Blood Adv. 2022;6: 2824–2834. pmid:35196375
- 43. Baillargeon J, Langevin A-M, Lewis M, Grady JJ, Thomas PJ, Mullins J, et al. Therapy-related changes in body size in Hispanic children with acute lymphoblastic leukemia. Cancer. 2005;103: 1725–1729. pmid:15754333
- 44. Rogers PC, Meacham LR, Oeffinger KC, Henry DW, Lange BJ. Obesity in pediatric oncology. Pediatr Blood Cancer. 2005;45: 881–891. pmid:16035086
- 45. Egnell C, Heyman M, Jónsson ÓG, Raja RA, Niinimäki R, Albertsen BK, et al. Obesity as a predictor of treatment‐related toxicity in children with acute lymphoblastic leukaemia. Br J Haematol. 2022;196: 1239–1247. pmid:34726257
- 46. Al-Mahayri ZN, AlAhmad MM, Ali BR. Long-Term Effects of Pediatric Acute Lymphoblastic Leukemia Chemotherapy: Can Recent Findings Inform Old Strategies? Front Oncol. 2021;11: 710163. pmid:34722258
- 47. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011;11: 886–895. pmid:22113164
- 48. Park J, Morley TS, Kim M, Clegg DJ, Scherer PE. Obesity and cancer—mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol. 2014;10: 455–465. pmid:24935119
- 49. Meeske KA, Siegel SE, Globe DR, Mack WJ, Bernstein L. Prevalence and correlates of fatigue in long-term survivors of childhood leukemia. J Clin Oncol. 2005;23: 5501–5510. pmid:16110010
- 50. Migita K, Takayama T, Matsumoto S, Wakatsuki K, Tanaka T, Ito M, et al. Impact of being underweight on the long-term outcomes of patients with gastric cancer. Gastric Cancer. 2016;19: 735–743. pmid:26298184
- 51. Dobner J, Kaser S. Body mass index and the risk of infection—from underweight to obesity. Clin Microbiol Infect. 2018;24: 24–28. pmid:28232162